Ocular TherapeutixTM to Present at Three Upcoming Investor Conferences

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at three upcoming investor conferences:

• 2017 BIO CEO & Investor ConferenceMonday, February 13, 2017 at 8:30 a.m. Eastern TimeThe Waldorf Astoria New York, New York, NY

• 2017 RBC Capital Markets Global Healthcare ConferenceThursday, February 23, 2017 at 9:00 a.m. Eastern TimeThe New York Palace Hotel, New York, NY

• 37th Annual Cowen and Company Healthcare ConferenceMonday, March 6, 2017 at 2:40 p.m. Eastern TimeThe Boston Marriott Copley Place, Boston, MA

Live audio webcasts of the presentations can be accessed through the Calendar of Events section of the Company's website at investors.ocutx.com. Replays of the webcasts will be available on the Company's website for two weeks following each presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix has resubmitted a new drug application (NDA) for post-surgical pain for its lead product candidate, DEXTENZA, which has completed Phase 3 clinical development for post-surgical ocular inflammation and pain. Subject to the approval of the NDA for post-surgical ocular pain, Ocular Therapeutix intends to submit a supplemental NDA for DEXTENZA to broaden its label to include an indication for post-surgical inflammation. DEXTENZA is also in Phase 3 clinical development for allergic conjunctivitis. OTX-TP is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170209005863/en/

Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief Financial Officer
[email protected]
or
Burns McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
[email protected]
or
Media
Medical Dynamics
Cynthia Sutherland, 646-599-8635
Media Group Director
[email protected]
or
Ocular Therapeutix, Inc.
Scott Corning
Vice President of Marketing & Commercial Operations
[email protected]

Source: Ocular Therapeutix, Inc.

You May Also Be Interested In

• RBC Capital Resumes BorgWarner (BWA) at Outperform
• Charter to Participate in Goldman Sachs Investor Conference
• HWH International Inc. Announces Executive Leadership Transition